{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:34:57Z","timestamp":1792870497549,"version":"4.5.0"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced\/metastatic HER2+ BC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>\n              In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.gov identifier:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03264547\">NCT03264547<\/jats:ext-link>\n              \/UMIN000027938), patients were randomly assigned (1:1) to receive eribulin 1.4 mg\/m\n              <jats:sup>2<\/jats:sup>\n              once daily on days 1 and 8 (eribulin group) or a taxane (docetaxel 75 mg\/m\n              <jats:sup>2<\/jats:sup>\n              once on day 1 or paclitaxel 80 mg\/m\n              <jats:sup>2<\/jats:sup>\n              once daily on days 1, 8, and 15; taxane group) intravenously in a 21-day cycle, each with HP on day 1. The primary end point was progression-free survival (PFS; intention-to-treat population). Secondary end points included objective response rate, overall survival (OS), patient-reported quality of life (QoL), and safety. Noninferiority was tested using the stratified Cox proportional hazards model to estimate hazard ratios (HRs) for PFS events, with a noninferiority HR margin of 1.33.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Between August 2017 and June 2021, 446 patients (median age, 56.0 years) were enrolled. The median PFS was 14.0 and 12.9 months in the eribulin group (n = 224) and taxane group (n = 222 [docetaxel\/paclitaxel, n = 186\/36]), respectively (HR, 0.95 [95% CI, 0.76 to 1.19]), which confirmed the noninferiority of the study regimen. The median OS was 65.3 months in the taxane group but has not been reached in the eribulin group. Median time to QoL deterioration was numerically longer with eribulin than with taxane. Adverse event (AE) rates were similar, despite the longer duration of eribulin use. Infusion reaction, skin-related AEs, diarrhea, and edema were more common with taxane, whereas neutropenia was more common with eribulin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>The results suggested that eribulin + HP is an option for first-line treatment of locally advanced\/metastatic HER2+ BC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/jco-24-01888","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T20:59:27Z","timestamp":1736456367000},"page":"1302-1313","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":15,"title":["Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2\u2013Positive Locally Advanced\/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03264547","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6479-1660","authenticated-orcid":true,"given":"Toshinari","family":"Yamashita","sequence":"first","affiliation":[{"name":"Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6732-8030","authenticated-orcid":true,"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-5291","authenticated-orcid":true,"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8490-9064","authenticated-orcid":true,"given":"Yoichi","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, National Cancer Center Hospital East, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Tsuneizumi","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-9158","authenticated-orcid":true,"given":"Akiyo","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-9598","authenticated-orcid":true,"given":"Masato","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Hokkaido University Hospital, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-6943","authenticated-orcid":true,"given":"Junji","family":"Tsurutani","sequence":"additional","affiliation":[{"name":"Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7162-1515","authenticated-orcid":true,"given":"Tsuguo","family":"Iwatani","sequence":"additional","affiliation":[{"name":"Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kitada","sequence":"additional","affiliation":[{"name":"Department of Breast Disease Center, Asahikawa Medical University Hospital, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2670-8982","authenticated-orcid":true,"given":"Hiroshi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Breast and Endocrine Surgery, Tohoku University Hospital, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Seirei Hamamatsu General Hospital, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6325-6124","authenticated-orcid":true,"given":"Toru","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Breast Unit, Japanese Red Cross Saitama Hospital, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-7715","authenticated-orcid":true,"given":"Kazuhiro","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, Gunma Prefectural Cancer Center, Gunma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Department of Surgery 1, Division of Breast Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Medical HQs, Eisai Co, Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Uchida","sequence":"additional","affiliation":[{"name":"Medical HQs, Eisai Co, Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4344-3317","authenticated-orcid":true,"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-0278","authenticated-orcid":true,"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_12_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.9984"},{"key":"e_1_3_12_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4968-7"},{"key":"e_1_3_12_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113216"},{"key":"e_1_3_12_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70130-X"},{"key":"e_1_3_12_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413513"},{"key":"e_1_3_12_7_2","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 6.2024. National Comprehensive Cancer Network. https:\/\/www.nccn.org"},{"key":"e_1_3_12_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"e_1_3_12_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-023-01505-x"},{"key":"e_1_3_12_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05576-6"},{"key":"e_1_3_12_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"e_1_3_12_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3144-y"},{"key":"e_1_3_12_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600261"},{"key":"e_1_3_12_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3633-7"},{"key":"e_1_3_12_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103375"},{"key":"e_1_3_12_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2014.04.004"},{"key":"e_1_3_12_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00991-6"},{"key":"e_1_3_12_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00755-x"},{"key":"e_1_3_12_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04341-y"},{"key":"e_1_3_12_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_12_21_2","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Japanese Clinical Oncology Group edition) [In Japanese]. http:\/\/www.jcog.jp\/doctor\/tool\/CTCAEv4J_20170310_miekeshi.pdf"},{"key":"e_1_3_12_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.6267"},{"key":"e_1_3_12_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.024"},{"key":"e_1_3_12_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.8213"},{"key":"e_1_3_12_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0773-6"},{"key":"e_1_3_12_26_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0079"},{"key":"e_1_3_12_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-016-0102-5"},{"key":"e_1_3_12_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.4887"},{"key":"e_1_3_12_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1608946"},{"key":"e_1_3_12_30_2","first-page":"135","article-title":"Clinical utility of eribulin mesylate in the treatment of breast cancer: A Chinese perspective","volume":"13","author":"Yuan P","year":"2021","unstructured":"Yuan P, Xu B.: Clinical utility of eribulin mesylate in the treatment of breast cancer: A Chinese perspective. Breast Cancer 13:135-150, 2021","journal-title":"Breast Cancer"},{"key":"e_1_3_12_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100074"},{"key":"e_1_3_12_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-24-01888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T22:01:15Z","timestamp":1744063275000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-24-01888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,4,10]]}},"alternative-id":["10.1200\/JCO-24-01888"],"URL":"https:\/\/doi.org\/10.1200\/jco-24-01888","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"2024-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}